New Phase 3 Study Shows that Gazyva® (obinutuzumab) Significantly Reduces Lupus Disease Activity in SLE
A new Phase 3 study published in the New England Journal of Medicine found that Gazyva® (obinutuzumab) significantly reduced disease...
Genentech
Driving Progress in Lupus Research: Highlights from the Lupus Research Alliance 2025 Forum for Discovery
LRA’s annual meeting brings together global leaders to accelerate breakthroughs in lupus The 2025 Lupus Research Alliance (LRA) Forum for...
2025 Lupus Research Alliance Gala Raises Millions to Bring New Treatments and a Cure
GRAMMY® Award-winning Artist Rob Thomas Headlines Evening Honoring Partners iHeart Media and Genentech The Lupus Research Alliance, the largest private...
Obinutuzumab Showed Significantly Positive Results in Published Phase III Lupus Nephritis Study
Exciting breaking news: A paper published in the highly prestigious journal New England Journal of Medicine and presented at...
LRA Forum for Discovery Showcases Cutting-Edge Lupus Research
The Lupus Research Alliance (LRA) hosted its highly anticipated annual scientific conference, Forum for Discovery (FFD), November 11-13 in...
Gazyva® Shows Positive Results in Phase 3 Lupus Nephritis Trial
The Lupus Research Alliance (LRA) and clinical research affiliate Lupus Therapeutics (LT) are excited to share positive news of...
Breadth of Clinical Research Presented at the 2019 ACR/ARP Annual Meeting Brings Hope for New Lupus Treatments
November 14, 2019
The Lupus Research Alliance staff was on the ground at the 2019 ACR/ARP Annual Meeting and highly...
Lupus Research Alliance Response to Positive Trial Testing Obinutuzumab (Gazyva®) for Lupus Nephritis
NEW YORK, Nov. 10, 2019 /PRNewswire/ -- The Lupus Research Alliance (LRA) is pleased to acknowledge positive results presented by...
Multi-ethnic Study Identifies New Genetic Markers for Lupus
Scientists from an international consortium have identified a large number of new genetic markers that predispose individuals to lupus.
The...